Applicant, as named in the Orange Book
Jazz Pharms Therap
Jazz Pharmaceuticals plc · Nasdaq: JAZZ
Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings
Next listed expiry: Vyxeos on 15 Apr 2033. 1 products with live protection, 0 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Vyxeos NDA 209401 cytarabine; daunorubicin | 15 Apr 2033 patent |
Recent events
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.